Marco Meglio, Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at email@example.com
Gait Dynamics Highly Associated With Autonomic Dysfunction in De Novo Parkinson Disease
Patients with high dysautonomia scores showed significantly slower walking speed, decreased cadence, and shorter stride but increased time than the lower scored group in backward gait.
Motor Symptoms Predate Prodromal Parkinson Disease by 3 Years, Study Finds
The case-control study identified numerous motor symptoms and signals that are associated with Parkinson disease diagnosis years after they begin to occur.
Sexual Dysfunction in MS Alleviated Through Antidepressant Bupropion
Over a 12-week trial, females with MS on bupropion demonstrated improvements in sexual satisfaction, sexual desire, vaginal moisture, and orgasm intensity.
Anti-CD20 Therapy Ublituximab Gains FDA Approval for Relapsing Multiple Sclerosis
Marketed as Briumvi, the TG Therapeutics treatment becomes the third anti-CD20 agent approved for relapsing multiple sclerosis and is expected to become available in the first quarter of 2023.
NeuroVoices: Eric Reiman, MD, on Entering a New Era of Prevention in Alzheimer Disease
The executive director of Banner Alzheimer’s Institute discussed the efforts being done within the field to improve prevention and therapeutics for Alzheimer disease.
Significant Differences in Perception of Cognitive Impairment in Multiple Sclerosis
Clinician perceived cognitive performance was significantly predicted by multiple factors, including cognitive scores, physical disability, age, and depression.
FDA Approves Insightec’s Exablate Neuro to Treat Second Side of Essential Tremor
Using focused ultrasound waves, the Exablate Neuro platform has now gained the FDA greenlight for medication-refractory essential tremor, tremor-dominant Parkinson disease, and second side of essential tremor.
Alzheimer’s Association Files Formal Request to Reverse CMS Provisions Against Anti-Amyloid Monoclonal Antibodies
The request to reverse CMS’s April 2022 decision is based on new data on lecanemab, an antiamyloid therapy from Biogen/Eisai that is currently under FDA review until January 6, 2023.
NeuroVoices: Miia Kivipelto, MD, PhD, on Using Multidomain Interventions to Prevent Cognitive Decline
The professor of clinical geriatric epidemiology at Karolinska Institutet provided perspective on the FINGERS trial, the first study to show it is possible to prevent cognitive decline using a multidomain lifestyle intervention.
FDA Pauses IND Submission for Duchenne Therapy ENTR-601-44
In preclinical studies, ENTR-601-44 has demonstrated a robust ability to skip exon 44 in the muscles of nonhuman primates and full-length human DMD mice.
Duchenne Agent WVE-N531 Shows Targeted Exon Skipping in Phase 1/2 Study
After 6 weeks of treatment, WVE-N531 was found to be safe, well-tolerated, and resulted in mean dystrophin production that was below the level of quantification.
Improving Biomarker Selection and Treating the Underlying Pathology of Dementia With Lewy Bodies
James Galvin, MD, MPH, director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine, provided insight on the unmet needs for dementia with Lewy bodies, and whether success in Alzheimer disease can help.
Patient-Reported Outcomes Improved Through Earlier Initiation of MS Treatment
Using a cohort of more than 2500 patients with MS on disease-modifying therapies, treatment initiation within the first 2 years of disease onset was more beneficial on patient-reported outcomes than 2-4 years postonset.
Short Sleep Duration, Poor Sleep Quality Both Associated With Weight Regain in Obese Individuals
Short objective sleep duration was associated with weight regain and attenuated improvements in body composition one year after weight loss, independent of intervention allocation, age, and sex.
COVID-19 and the Brain: Understanding the Neurological Effects of the Virus as the Pandemic Evolves
Almost 3 years since the beginning of the pandemic, continuous research efforts have begun to paint a better picture of the impact the virus has on the brain and the central nervous system.
First-Ever Genetic Links Found in Progressive Multifocal Leukoencephalopathy
In the largest collected of PML DNA samples, the study identified 4 immune-linked, high effect size, rare variants for use in an iatrogenic PML risk genetic test.
Myotonic Dystrophy Agent AOC 1001 Demonstrates Successful Targeted Delivery of RNA
AOC 1001, an agent consisting of a proprietary monoclonal antibody that binds to the transferrin receptor 1, was safe, tolerable, and showed significant reductions in DMPK, a disease-related mRNA.
Educational Videos Improve CPAP Adherence in Obstructive Sleep Apnea
Although the effects of the educational intervention weren’t seen at 3 months, investigators noticed significant differences relative to standard of care at 12 months.
NeuroVoices: Susan Abushakra, MD, on the Potential Role of ALZ-801 Within the Alzheimer Treatment Landscape
The chief medical officer of Alzheon detailed the efficacy, safety, and potential of ALZ-801, an investigational anti-amyloid therapy being assessed in high-risk individuals with early Alzheimer disease.
BrainStorm Submits Type A Meeting Request Regarding NurOwn ALS Treatment
In a phase 3 trial, NurOwn failed to meet its primary end point of change on ALSFRS-R; however, the therapy showed significant benefits in those with less severe forms of ALS.
Hydromethylthionine Mesylate’s Place as a Potential Tau Aggregator of Alzheimer Disease
Bjoern Schelter, MD, Data Analytics and Biostatistics lead at TauRx, provided background on the efficacy, safety, and role of HMTM as a treatment for cognition in pre-Alzheimer disease stages like mild cognitive impairment.
Fueling Research Focused on Improving Diagnosis and Therapeutics in Alzheimer Disease
Howard Fillit, MD, founding executive director of the Alzheimer’s Drug Discovery Foundation, provided perspective on how ADDF and others are advancing the detection and treatment of Alzheimer disease.
Real-World Italian Survey Study Provides Insight on SMA Prevalence in Age of New Therapeutics
High rates of treatment use were observed across all types of spinal muscular atrophy, with nusinersen, the first approved disease-modifying treatment, as the most commonly used.
Range of Risk Factors, Comorbidities, and Prodromal Features Identified Prior to Parkinson Disease
Subsequent diagnosis of Parkinson disease was associated with a range of risk factors such as alcohol misuse and traumatic head injury, along with several other comorbidities and prodromal features.
Ultraprocessed Food Consumption Association With Increased Risk of Cognitive Decline
Percentage of daily energy from ultraprocessed food was associated with cognitive decline in participants younger than 60 years, suggesting the importance of preventive interventions in middle-aged adults.
Behavioral Treatment for Insomnia Shows Short-Term Potential to Improve Trauma-Related Nightmares
More than half of the patients who reported at least 1 trauma-related nightmare showed decreases after starting brief behavioral treatment.
Fenfluramine Continues to Show Effectiveness, Safety in Long-Term Analysis of Lennox-Gastaut
After nearly a year of treatment with fenfluramine, more than half of patients with Lennox-Gastaut syndrome demonstrated at least a 50% reduction in drop seizure frequency.
NeuroVoices: Sube Banerjee, MD, MSc, MBA, FRCPsych, on Replacing Traditional Noneffective Agents for Alzheimer Agitation
The professor of dementia and executive dean of the Faculty of Health at the University of Plymouth provided perspective on the SYMBAD trial, and eliminating the use of mirtazapine and carbamazepine as medications to treat Alzheimer agitation.
Raising the Overall Awareness for Infantile Spasms, Early Recognition of Pre-Epilepsy Diagnosis
Martina Bebin, MD, MPA, professor of neurology, University of Alabama at Birmingham Epilepsy Center, discussed Infantile Spasms Awareness Week, the strides made within the field, and the emphasis on early and accurate diagnosis.
DNL343 to be Assessed in HEALEY ALS Platform Trial Following Positive Phase 1 Findings
After showing robust inhibition of biomarkers associated with integrated stress response, the eIF28 modulator will be assessed alongside several other potential agents in the HEALEY ALS Platform trial.
2 Clarke Drive Cranbury, NJ 08512